JAK/STAT inhibitors decrease CRS-associated cytokines and symptoms in mice, and ITK inhibitors lengthen survival in mice and improve clinical outcomes in patients, with reduced incidence of CRS. This evidence concerns the gene ITK and congenital rubella syndrome.